Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™

Key Terms

enzyme replacement therapy medical

Enzyme replacement therapy is a medical treatment that involves providing patients with artificial versions of natural enzymes their bodies are missing or not producing enough of. This approach can help manage certain health conditions by restoring essential functions, similar to replacing a faulty part in a machine to keep it running smoothly. For investors, advancements or approvals in this therapy can signal progress in biotech innovation and potential market growth.

heparan sulfate medical

Heparan sulfate is a long, chain-like sugar molecule found on the surface of most cells and in the spaces between them, acting like tiny antennae and Velcro that help cells communicate, stick together, and interact with proteins, including some viruses and drugs. Investors should care because it is a common biological entry point and regulator for therapies and diagnostics; drugs that target or use heparan sulfate pathways can affect efficacy, safety, and market potential in biotech and pharmaceutical development.

cortical gray matter volume medical

Cortical gray matter volume is the amount of tissue in the brain’s outer layer where nerve cell bodies and local connections live, usually measured with MRI scans. Investors care because changes in this volume can signal disease progression or improvement from treatments for neurological or psychiatric conditions, acting like a measurable yardstick—similar to tracking a building’s square footage to judge damage or renovation—used to evaluate drug effects and market potential.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data on the long-term administration of its tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfillipo syndrome type B (MPS IIIB) will be presented at the 22^nd Annual WORLDSymposium™ taking place February 2-6, 2026 in San Diego. A second presentation will detail divergent outcomes in two male siblings, one of whom was treated with TA-ERT in a clinical trial while the other received care without treatment.

WORLDSymposium 2026 Presentation Details

Title: Long-term administration of tralesinidase alfa enzyme replacement therapy (TA-ERT) results in profound and durable reduction of heparan sulfate (HS) and stabilization of cognitive function and cortical gray matter volume (CGMV) in patients with Sanfilippo syndrome type B (MPS IIIB)​
Platform Presentation Date & Time: 1:42 – 1:54 p.m. PT on February 5, 2026
Location: Harbor Ballroom
Presenter: Nicole Muschol, M.D., International Center for Lysosomal Disorders (ICLD) at the University Medical Center Hamburg-Eppendorf in Germany
Authors: Nicole Muschol, M.D.; Mona Lindschau, M.D.; Ilyas Okur, M.D.; Fatih Ezgu, M.D.; Maria J. de Castro Lopez, M.D.; Spyros Batzios, M.D.; Igor Nestrasil, M.D.; Saba Sile, M.D.; Ting Chang, Ph.D.; Jeffrey Zhang, Ph.D.; Javier Szwarcberg, M.D., M.P.H.; Paul Harmatz, M.D.

These data will also be presented as poster #259 on February 5 from 3:30 – 5:30 p.m. PT at Kiosk 30-B

Title: Divergent neurocognitive outcomes in mucopolysaccharidosis (MPS) type IIIB siblings:​ Tralesinidase alfa versus supportive management​ (poster #64)
Poster Presentation Date & Time: 3:30 – 5:30 p.m. PT on February 5, 2026
Location: Kiosk 8-C
Presenter: Irene J. Chang, M.D., Assistant Professor at the University of California, San Francisco
Authors: Irene J. Chang, M.D.; Jacqueline Madden, P.N.P.; Erin Jozwiak, N.P.; Saba Sile, M.D.; Ting Chang, Ph.D.; Javier Szwarcberg, M.D., M.P.H.; Paul Harmatz, M.D.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook and YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260128573673/en/

Media

Carolyn Hawley

Inizio Evoke Comms

Carolyn.Hawley@inizioevoke.com

media@sprucebio.com

Investors

Samir Gharib

President and CFO

Spruce Biosciences, Inc.

investors@sprucebio.com

Source: Spruce Biosciences, Inc.